OOIR: Observatory of International Research

Papers

(The TQCC of Clinical Lymphoma Myeloma & Leukemia is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
SOHO State of the Art Updates and Next Questions \| Approach to BCR::ABL1-Like Acute Lymphoblastic Leukemia	38
Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no	36
P-112 Fall Risk Assessment and Fall Prevention in Patients With Multiple Myeloma: First Results of the MYFALL-Trial	35
P-154 Multidisciplinary, Patient-Centric Bone Disease Management in Multiple Myeloma – a Single-Centre Experience	31
P-186 Identifying a New Risk-Stratification Strategy by Including Single-Cell Biomarkers in Multiple Myeloma	28
P-330 Stem Cell Mobilization Strategy With Pegilgrastim for Stem Cell Transplantation for Multiple Myeloma: A Direct Cost Comparison	27
P-202 Risk Factors Predicting Early Relapse for Newly Diagnosed Multiple Myeloma Patients Treated with Front-Line VRD Regimen	27
P-309 Diagnostic Challenges in Systemic Amyloidosis: Exploring the Impact of Mass Spectrometry in a Middle-Income Country Cohort	26
P-232 Comprehensive Genomic Sequencing Predicts Sub-Optimal Response to Bispecific Antibodies (BsAb) and Chimeric Antigen Receptor T Cells (CAR-T) in Multiple Myeloma (MM)	25
P-342 Impact of Achieving <VGPR With Dara-RVD Induction Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients	24
OA-27 Para-Medullary (PMD) and Extra-Medullary (EMD) Myeloma Demonstrate Increased Copy Number Aberration, Mutational Burden, Structural Variants and Genomic Complexity Compared to Marrow-Based Myelom	24
P-012 Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma	23
P-113 An Artificial Intelligence-Based 3D-Segmentation Assessment of Sarcopenia Utilizing Whole-Body Computed Tomography in Patients With Multiple Myeloma	21
P-455 Survey of multiple myeloma (MM) patients and healthcare professionals (HCPs) on the relevance of existing health quality-of-life (QoL) questionnaires (QoLQ) to real-world QoL issues of MM patien	21
P-068 Developing Novel DKK1-A2 CAR-T Cell Therapy for Myeloma and Other Hematologic Malignancies	21
P-100 Prevalence of monoclonal gammopathies in adult Uruguayan population	21
Management Challenges in Patients with Treatment-Free Remission of Chronic Myeloid Leukemia	19
Demographic Characteristics of Hospitalized Patients With History of Multiple Myeloma in Remission: Insights From National Inpatient Sample 2021	19
MM-731 Prognostic Implications of Immune Paralysis in Newly Diagnosed Multiple Myeloma	19
OA-38 Physical activity interventions to improve functional performance in patients with multiple myeloma	19
MPN-153 A Phase 1b Trial of DISC-0974, an Antihemojuvelin Antibody, in Participants With Myelofibrosis and Anemia	19
P-139 Impact of melphalan staggered dosing prior to autologous hematopoietic cell transplantation for multiple myeloma patients	19
CT-244 Updated Clinical Progress of IL-10 expressing CD19 CAR-T Cells for Treatment of Relapsed or Refractory B-Cell Hematological Malignancies at Tiny Doses	18
IBCL-381 Studying the Impact of CD38 Expression on Extracellular Adenosine and Its Connection With the PD1/PDL1 Axis in Mature B-Cell Lymphoma Patients	18
Utility of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma Patients – A Single Institution Experience From Pakistan	18

MM-542 Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab Bortezomib, and Dexamethasone in Pati	18
Therapeutic Efficacy of Acupuncture Combined With Pharmacology in Bortezomib-Induced Peripheral Neuropathy	17
ABCL-440 Preliminary Safety and Efficacy Data of Combination Polatuzumab Vedotin Rituximab, Cyclophosphamide Adriamycin, Prednisone (Pola-R-CHP) in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)	17
MM-597 Diarrhea in Multiple Myeloma Autologous Stem Cell Transplant Recipients: Think Beyond Mucositis	17
Barriers to Receiving Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Insights From a Large-Scale Multicenter Observational Study	17
Frequency of Practice-Changing Findings Identified by Comprehensive Genomic Profiling in Non-Myeloid Hematologic Malignancies	17
Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens (SRs) in Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Sub-Analysis of Black Patients	16
ALL-441 Outcome of Adult Acute Lymphoblastic Leukemia, a Single-Center Experience	16
MPN-307 Systemic AA Amyloidosis as a Complication of Idiopathic Multicentric Castleman's Disease	16
CML-674 Molecular Screening of Tyrosine Kinase Inhibitor Resistance in Tunisian Patients With Chronic Myeloid Leukemia	15
Evaluating the Impact of an Electronic Medical Record (EMR) Alert on Appropriate Dosing of Luspatercept in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Community Oncology Network	15
CLL-656 Multiplex ligation-dependent probe amplification (MLPA): Utility as a first line screening tool for detection of clinically relevant genomic aberrations in CLL	15
CT-175 The Impact of Diabetes Mellitus on Hematopoietic Stem Cell Mobilization	14
MM-645 Updated OS of Patients With AL Amyloidosis After CAEL-101	14
Accessing BTK Inhibitors and Other Novel Therapies for Mantle Cell Lymphoma: Are We All Invited to the Party?	14
Dose-Adjusted Melphalan Yields Comparable MRD-Negativity to Full-Dose Melphalan in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant	14
Limited Toxicity and Impressive Outcomes of Upfront Flag-Based Induction in Newly Diagnosed Acute Myeloid Leukemia: An Indian Scenario	14
Olutasidenib Demonstrates Promising Tolerability and Efficacy in IDH1-Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms	14
CML-627 Concomitant Acid-Reducing Agents With TKI Increases Time to Achieve Remission in Patients With CML: A Real-World Analysis of a US Claims Database	14
Time-Dependent Transfusion Status as an Independent Predictor of Overall Survival: A Post Hoc Analysis of 3 Phase 3 Trials	14
Influence of Heart Failure Upon Incidence Rates of Pneumonia, Acute Respiratory Failure, Sepsis and Septic Shock in Patients With Polycythemia Vera	14
Higher Relapse Rate and Resource Utilization With Ara-C Consolidation Chemotherapy Alone Compared With Hematopoietic Cell Transplantation in First Remission in a Cohort of Younger Adults With Acute My	13
Epidemiological Profile and Outcomes of Patients Admitted to the Intensive Care Unit at Yeolyan Hematology and Oncology Center: A Retrospective Study	13
Phase 3 BELLWAVE-010: Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab (VR) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)	13
Monoclonal Insulin Autoimmune Syndrome Successfully Treated With Plasma Cell Directed Therapy	13
Efficacy and Safety of Ciltacabtagene Autoleucel ± Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma With Suboptimal Response to Frontline Autologous Stem Cell Transplant: CARTITUDE-2 Cohor	13
Management of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice: A Focus on Patient Outcomes Post Erythropoiesis-Stimulating Agent (ESA) Treatment	13
Neurolymphomatosis: An Unusual Manifestation of Relapsed/Refractory Lymphoma	13
MDS-570 NPM1-Mutated Myeloid Neoplasms Irrespective of Blast Count Are Associated With Better Outcomes With Acute Myeloid Leukemia Treatment Approach	13
Association Between Hemoglobin Improvement and Patient-Reported Outcomes in Patients With Myelofibrosis and Anemia: Post Hoc Pooled Analysis of Momelotinib Phase 3 Trials	13
Outcomes of Bone Marrow Transplant in ESRD vs Non-ESRD Patients: A Nationwide Analysis	13
IBCL-541 A Comprehensive Single-Cell Multi-Omic Analysis to Depict the Biological Heterogeneity of Follicular and Large B-Cell Lymphomas	13
P-200 MAP4K2 inhibition reinforces sensitivity to iberdomide in RAS-mutated MM through a CRBN-independent mechanism	12
OA-22 TiMMing: developing an innovative suite of bioinformatic tools to harmonize and track the origin of copy number alterations in the evolutionary history of multiple myeloma	12
P-266 Pre-clinical characterization of SAR442257, a CD38xCD28xCD3 trispecific T-cell engager in relapsed/refractory multiple myeloma	12
P-361 Genomic and transcriptomic landscape of hyper-APOBEC multiple myeloma	12
Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study	12
POSTER: CLL-773 Real-World Outcomes of BTK Inhibitors (BTKi) in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients With Preexisting Cardiovascular Comorbidities	12
MM-1419: Pooled Incidence of Cytokine Release Syndrome in Talquetamab Therapy for Relapsed/Refractory Multiple Myeloma: A Systematic Review	12
P-383 A 16-gene signature reflecting tumor microenvironment predicts the risk of multiple myeloma patients treated by bortezomib-based therapies	12
Expert Opinion on Multiple Myeloma Treatment in Brazil in the Bispecific Antibody Era	12
P-309 ZnDDC, a novel CELMoD-like agent binding to DDB1-CRBN complex demonstrates significant synergism with BTZ and IMiDs and overcomes IMiDs resistance in myeloma cell lines and primary samples	12
P-278 Estimating the size of patients with relapsed/ refractory multiple myeloma treated with 1-3 and 4 or more prior lines of therapy in the United States	12
Impact of Facility Type on Survival in Chronic Myelomonocytic Leukemia: A Propensity Score Matched, National Cancer Database Analysis	12
MPN-1333: Essential Thrombocythemia (ET) Presenting as Bilateral Adrenal Hemorrhage in an Older Adult Patient: A Rare Clinical Manifestation of a Myeloproliferative Neoplasm (MPN)	12
P-138 Real World Single Centre Experience On The Use of Radiotherapy In The Treatment of Patients with Multiple Myeloma	12
P-378 Longitudinal antibody and T-cell kinetics over four doses of COVID-19 vaccination and predictors of poor response in patients with multiple myeloma	12
Editorial Board	12
OA-08 GPRC5D-targeted CAR-T cell therapy in patients with relapsed or refractory multiple myeloma progressing after or refractory to BCMA CAR-T cell therapy: updated eesults from a phase 2 clinical tr	12
P-314 Daratumumab for Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin G Deposits and Severe Chronic Kidney Disease	12

Treatment Patterns, Efficacy, and Tolerability of Belantamab Mafodotin in Patients With Relapsed and/or Refractory Multiple Myeloma: A Real-World Analysis	12
ALL-031: Outcome of Adult Acute Lymphoblastic Leukemia: A Single-Center Experience	12
POSTER: AML-481 Treatment Outcomes of All-Trans Retinoic Acid, Arsenic Trioxide, and Daunorubicin in High-Risk Pediatric Acute Promyelocytic Leukemia: A Single-Center Study From a Quaternary Care Cent	11
EXABS-230-ABCL: Potential of AI Remote Patient Monitoring for Lymphoma	11
Delphi Survey on Measurable Residual Disease in Multiple Myeloma: Prevailing Practices and the Way Forward in India	11
CT-696: Results of Low-Dose Cyclophosphamide in GVHD Prevention After Allo-HSCT for Acute Leukemia in Uzbekistan	11
POSTER: ABCL-167 Post-Transplant Lymphoproliferative Disorder: Key Considerations and Real-World Analysis in a University Hospital in Northeastern Brazil	11
ALL-160: A Retrospective Analysis of Molecular Markers in Patients Diagnosed With Acute Lymphoblastic Leukemia in 4 Consecutive Years—A Single-Center Experience	11
POSTER: MPN-1441 Thrombosis Before Diagnosis: A 22-Year National Analysis of Missed Opportunities in Polycythemia Vera and Essential Thrombocythemia	11
EXABS-136-LYM: Management of Burkitt Lymphoma	11
POSTER: AML-983 Evaluating ChatGPT’s Responses to Commonly AskedQuestions in Allogeneic Hematopoietic Stem Cell Transplantation: A Physician-Based Assessment	11
POSTER: ABCL-1113 Safety and Efficacy of AZD0486, a CD19 × CD3 T-Cell Engager, in Relapsed or Refractory Diffuse Large B-Cell Lymphoma	11
MM-718: Lisaftoclax (APG-2575) Combined With Novel Therapeutic Regimens in Patients With Relapsed or Refractory (R/R) Multiple Myeloma (MM) or Immunoglobulin Light-Chain (AL) Amyloidosis	11
Practical Guidance on the Clinical Management of Belantamab Mafodotin for Patients With Relapsed/Refractory Multiple Myeloma: Recommendations From the Middle East and North Africa Expert Panel	11
POSTER: CLL-1245 Longitudinal Single-Cell Profiling of CLL Patients Exposed to BTK and BCL2 Inhibitors	11
POSTER: AML-114 All-Trans Retinoic Acid and Arsenic Trioxide versus All-Trans Retinoic Acid and Chemotherapy in Acute Promyelocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials	11
POSTER: MM-1153 Thromboprophylaxis Using Factor Xa Inhibitors Provides Better Outcomes Than Traditional Anticoagulants in Multiple Myeloma Patients Undergoing Immunomodulatory Therapy: A Systematic Re	11
MCL-1122: A SEER Study on Incidence and Survival Trends in Mantle Cell Lymphoma Involving Tonsils	11
HL-477: Who Should We Screen for Germline Cancer Predisposition in Pediatric Lymphoma?	10
POSTER: AML-995 QuANTUM-Wild: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in FLT3-ITD–Negative Acute M	10
MCL-365: Mantle Cell Lymphoma and Cisplatin-Induced Hyponatremia: A Case Report	10
CT-1344: Real-World Experience With Ruxolitinib for Steroid-Refractory Acute Graft-vs-Host Disease in a Latin American Center	10
CLL-1044: Beyond the Stage: The Evolving Landscape of Cytogenetic Risk in African Americans With CLL and Its Impact on Clinical Strategies	10
POSTER: ABCL-755 Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma (NHL)	10
POSTER: TCL-1001 Tumor Microenvironment Profiling in Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma Using Codex Multiplex Imaging	10
CT-1329: Trends in Anemia- and Pneumonia-Related Mortality (1999–2023): A CDC WONDER Database Analysis	10
MPN-524: Phase 3 Study Comparing Ropeginterferon Alfa-2b With Anagrelide As Second-Line Treatment for Essential Thrombocythemia: SURPASS-ET Trial	10
POSTER: IBCL-416 Treatment Preferences of Patients, Caregivers, and Physicians in Follicular Lymphoma (FL): A Global Discrete-Choice Experiment (DCE) Study	10
POSTER: ABCL-361 Time-Limited Antithrombotic Prophylaxis Reduces the Risk of PICC-Related Thrombosis in Patients With Aggressive B-Cell Lymphoma Receiving DAEPOCH-R	10
POSTER: AML-686 Diagnostic Yield of Bronchoscopy in Patients With Hematological Malignancies	10
TCL-1041: Aggressive CD56-Negative T-Cell Large Granular Lymphocyte Leukemia With Liver Infiltration in a Young Adult: A Rare Case Report	10
POSTER: CT-1454 CAR T-Cell Therapy in the Treatment of Relapsed/Refractory Aggressive B-Cell Lymphomas	10
POSTER: MM-846 Global Disparities in Multiple Myeloma Outcomes: A World Health Organization Region-Based Analysis of Survival Proxies and Health System Indicators	10
MM-1377: Balancing Efficacy and Safety: Apixaban vs Rivaroxaban in Multiple Myeloma-Associated Thrombosis and Clinical Outcomes	10
POSTER: CT-230 Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Marginal Zone Lymphoma (MZL) in the Phase 2 TRANSCEND FL Study	10
MM-547: Role of IL10 Single-Nucleotide Variation in Multiple Myeloma	10
POSTER: CML-1112 Pregnancy Outcomes in Women With Chronic Myeloid Leukemia: A Single-Center Experience From Pakistan	10
AML-1467: Adiposity-Driven Leukemogenesis: Global Trends in Acute Myeloid Leukemia Attributable to High BMI Across 204 Countries (1990–2021)	9
IBCL-341: Fixed-Duration Subcutaneous Mosunetuzumab in Patients With Previously Untreated High-Tumor Burden Follicular Lymphoma (FL): Interim Results From the Phase 2 MorningSun Study	9
POSTER: CT-929 Resolution of Infectious Episodes Through Surgical Interventions in Severely Neutropenic and Thrombocytopenic Patients	9
POSTER: MM-872 Racial Disparities in Clinical Outcomes Among Patients With Newly Diagnosed Multiple Myeloma in the United States: A 21-Year Comparative Analysis	9
POSTER: CT-087 Preliminary Insights into CAR-T Therapy for Melanoma: A Systematic Review	9
POSTER: MDS-307 Acquired Platelet Dysfunction Secondary to Myelodysplastic Syndrome: Successful Resolution With Syndrome-Directed Therapy	9
ORAL ABSTRACT: ALL-712 Can Chimeric Antigen Receptor T-Cell Therapy Be a Definitive Treatment for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Without Stem Cell Transplant? Long-Term	9
IBCL-1447: Outcomes of Hairy Cell Leukemia Treatment: A Single Center Experience	9
MDS-1306: Survival Trends and Prevalence Disparities in Refractory Anemia With Ringed Sideroblasts	9
CLL-563: Bexobrutideg (NX-5948), a Novel Bruton's Tyrosine Kinase Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Findings from	9
TCL-1382: Evaluating Mortality Trends and Disparities Related to T-Cell Lymphomas Among Adults in the United States: A Retrospective Analysis of Two Decades	9
AML-666: Mutational Landscape of the RTK-RAS Signaling Pathway in Acute Myeloid Leukemia: Insights From Whole-Exome Sequencing	9
AML-1129: Racial and Ethnic Differences in the Outcomes of Acute Myeloid Leukemia Among Adolescent and Young Adult Patients: Insights From the SEER Database	9
POSTER: MCL-611 Complete Response in Heavily Pretreated Refractory Mantle Cell Lymphoma After Bendamustine and Glofitamab: A Paradigm Shift in Immunotherapy Sequencing	9
POSTER: ABCL-501 Treatment of Mediastinal Gray Zone Lymphoma After Progression on First-Line Therapy Including Rituximab: Treatment With High-Dose Therapy, Nivolumab and Ipilimumab	9
HL-439: Superadded HLH in a Child With Hodgkin Lymphoma and Concurrent EBV Viremia: Case Report	9
POSTER: ABCL-475 5-Year Analysis of the POLARIX Study: Prolonged Follow-Up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on	9
AML-976: V-RULES: Impact of Treatment Setting on CPX-351 Safety and Effectiveness in Secondary Acute Myeloid Leukemia	8
CT-1338: Impact of Depression on In-Hospital Outcomes Among Patients Undergoing Bone Marrow Transplantation: A National Inpatient Sample Analysis	8
EXABS-176-AML: How to Best Incorporate FLT3 Inhibitors in the Management of FLT3-Mutated AML	8
IBCL-783: High CR and MRD Negativity Rates With GLPG5101, a Fresh, Stem-Like, Early Memory CD19 CAR T With 7-Day Vein-to-Vein Time: Full Results From ATALANTA-1 Cohort 3 (iNHL)	8
Cevostamab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM): Phase I Dose-Expansion Results from the CAMMA 1 Study	8
Exploring Molecular Glues to Activate Proteasomes and Develop Shared and Personalized Neoantigen-Based Therapeutics in Multiple Myeloma	8
Composition and Functional State of T and NK Cells in Extramedullary Myeloma Tumor Microenvironment	8
CLL-1397: Genetic and Mutational Characterization in Patients With Chronic Lymphocytic Leukemia at the Guatemalan Social Security Institute	8
MPN-537: Decoding Myeloid Neoplasms: The Transformative Role of Next-Generation Sequencing in Hematology Oncology—Real-World Data From Resource-Constrained Settings	8
MM-145: Clinical characteristics and molecular genetic factors in patients with extramedullar bone lesions	8
ABCL-1061: Prevalence and Clinical Outcomes of Hepatitis B Virus Seropositivity in Lymphoma Patients Undergoing Rituximab-Based Therapy	8
POSTER: CLL-950 Chronic Lymphocytic Leukemia Mortality in the US (1999–2023): A National Analysis From CDC WONDER	8
The Value of Progression-Free Survival (PFS) from the Perspectives of Patients with Multiple Myeloma (MM) and Treating Physicians: Quantitative Research Findings from Eight Countries	8
CALM: A Deep Learning Time Series Model for Predicting Progression from Smoldering Multiple Myeloma Using Clinical Data	8
Outcomes of Teclistamab (Tec) Step-Up Dosing in Outpatient/Hybrid Settings Among a Large Sample of Relapsed Refractory Multiple Myeloma (RRMM) Patients Treated with Tec	8
POSTER: AML-1290 Outcomes in Patients Younger Than 50 Years Old (yo) With Treatment-Naive Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated With Tagraxofusp: Subanalysis of a Phase 1/2 Tria	8
AML-1252: Equitable Overall Survival in AML With Hypomethylating Agent and Venetoclax Despite Medically Underserved Area or Driving Distance: A Comparative Cohort Analysis Including Intensive Chemothe	8
MM-101: Iberdomide (IBER), Daratumumab (DARA), and Dexamethasone (DEX) (IberDd) in Transplant-Ineligible (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Results From the Phase 1/2 CC-220-MM-001 Trial	8
ALL-852: Retrospective Analysis of Hepatotoxicity Associated With Inotuzumab Therapy in B-Cell Acute Lymphoblastic Leukemia: Describing a New Clinical Phenomenon Called Calicheamicin Syndrome	8
SOHO State of the Art Updates and Next Questions: BTK inhibitors combined with chemoimmunotherapy in CLL, the best of both worlds?	8
BCMA CAR T-Cell Therapy in Newly Diagnosed Transplant-ineligible Multiple Myeloma: An Open Label, Single-arm, Phase 2 Study (CAREMM-001)	8
Assessing the Clinical Implications and Prognostic Value of Light-Chain N-Glycosylation in 781 Multiple Myeloma Patients at Diagnosis	8
Recent Trends in Real-World Frontline Treatment Patterns and Outcomes for Patients with Multiple Myeloma in the United States	8
P-020: PD1-based chimeric-switch receptor expressing NK cells recover from immune checkpoint inhibition in cancer	7
Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study	7
Current Survival and Causes of Mortality of Myeloma Patients in Real Word Setting	7

High-Throughput Chemical Biology Screens Unravel Precision Medicine Strategies for Multiple Myeloma	7
Dynamic Prediction of Progression Based on Minimal Residual Disease (MRD) in Patients with Newly Diagnosed Transplant Eligible Multiple Myeloma	7
Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma	7
EXABS-161-MPN Management of Pre-Fibrotic Primary Myelofibrosis	7
P-141: Prognostic impact of CD3/CD34 ratio in apheresis collection in multiple myeloma patients undergoing autologous stem cell transplant	7
OA-14 Prospective Functional Bone Disease Evaluation of Newly Diagnosed Multiple Myeloma with Combined Use of (18)F-FDG-PET/CT and Whole-Body Diffusion Weighted Magnetic Resonance	7
A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies	7
CT-009 Prognostic Role of Lymphocyte to Monocyte Ratio in PTS Treated With CAR-T for Aggressive Lymphoma	7
Outcomes after Second Autologous Hematopoietic Cell Transplant in Patients with Relapsed Multiple Myeloma in Latin America	7
Real-World Outcomes of SLiM-Only Multiple Myeloma: Korean Multicenter Retrospective Analysis	7
Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) is Associated With Better Overall Survival	7
P-430 Incidence of primary plasma cell leukemia with the new diagnostic criteria	7
MDS-304 Disparities in Myelodysplastic Syndromes Mortality Among Older Adults in the United States: A CDC WONDER Database Analysis	7
AML-194 Second Hematological Malignancies in Survivors of Breast Cancer: An Indian Institutional Analysis	7
The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study	7
Ixazomib With or Without Rituximab Following Maintenance Autologous Stem Cell Transplant in Mantle Cell Lymphoma: A Single-Center Phase I Trial	7
Evaluation of Clinical Characteristics and Prognostic Factors of Early Progressive Disease (EPD) in Newly Diagnosed Multiple Myeloma Patients: Real-World Data of the Greek Myeloma Study Group	7
Health-Related Quality of Life in Indian Patients with Multiple Myeloma: A Pan-India Digital Survey-Based Assessment	7
AVicious Cycle Between Sensory Nerve Outgrowth and Myeloma Tumor Progression in the Bone Marrow	7
Quadruplet Therapy and ASCT in Multiple Myeloma: Does It Increase Toxicity?	7
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial	7
OAB-056: Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a Phase 1/2 study in patients with relapsed/refractory multipl	7
P-097: A novel anti-BCMA lipid-based nanoparticle for multiple myeloma therapy	7
MM-492 Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)	7
AML-271 Acute Stroke Secondary to Patent Foramen Ovale (PFO) in Patients With Acute Myeloid Leukemia (AML)	6
Poster: MM-474 Minimal Residual Disease Perception and Utilization in Real-World Multiple Myeloma Treatment	6
MM-459 Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis	6
P-100: Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma	6
POSTER: AML-112 Impact of Consolidation Chemotherapy Intensity Before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients With Acute Myeloid Leukemia	6
Poster: TCL-084 Subcutaneous Panniculitis-Like T-Cell Lymphoma With Co-Existing Lupus Panniculitis: A Case Report	6
MM-508 Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma: A Real-World Observational Study Update	6
POSTER: MM-638 Role of the Combination of FDG-PET plus Whole Body MRI for Staging Newly Diagnosed and Relapsed/Refractory Multiple Myeloma (MM): A Prospective Trial	6
POSTER: MPN-183 Interferon Treatment Suppresses In Vitro NETosis in Neutrophils Derived from Patients With Myeloproliferative Neoplasms	6
Poster: ABCL-523 Immunohistochemical (IHC) Expression of Epigenetic Regulators (EZH-2 and H3K27) as well as Cell Cycle Regulators (P16, P53 and RB) in Patients Diagnosed With Primary Diffuse Large B-C	6
P-212: Quantifying the average treatment effect of single vs. tandem autologous stem cell transplantation in newly diagnosed multiple myeloma using causal inference	6
AML-327 Novel Anti–B7-H3 Blocking Antibody Enhances NK Cell–Mediated Cytotoxicity and Improves Outcomes in AML-Bearing Mice	6
OAB-053: Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)	6
Poster: CT-195 Predictive Value of ST2, REG3a, and MAGIC Algorithm in Haploidentical Transplantation With Post-Transplant Cyclophosphamide Outcomes	6
Poster: CT-227 Dual CAR-Engineered NK92 Cells: An Off-the-Shelf Cell Therapy for Cancer	6
POSTER: HL-281 Treatment of Relapsed Hodgkin Lymphoma With Pembrolizumab as Monotherapy	6
Association Of -308G/A, -238G/A TNF-α Polymorphisms with Multiple Myeloma Risk and Survival: A Systematic Review and Meta-Analysis	6
Poster: CLL-517 Hypertension as an Adverse Event of Ibrutinib: Does Age Matter?	6
Evaluating Response Trends of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: Analysis of Individual Patient Data From a Randomized Controlled Phase II Study to Facili	6
P-001: RNA-sequencing reveals transcriptomic similarity of AL amyloidosis and MGUS aberrant plasma cells along with several potential ALA target candidate genes	6
TCL-306 Application of the Proposed Immunohistochemistry Algorithm for the Prognostication of GATA3 and TBX21 Subtypes of Peripheral T-Cell Lymphoma, Not Otherwise Specified	6
MM-369 Clinical Diversity of Multiple Myeloma Over Time, From First Presentation to Diagnosis, in Kurdistan Region, Iraq	6
ABCL-269 Secondary Central Nervous System (CNS) Involvement in Diffuse Large B Cell Lymphoma (DLBCL): Ten-Year Outcomes From Mexico's National Cancer Institute	6
EXABS-147-AML How Do We Overcome Resistance to Venetoclax	6
Poster: MM-198 Anti-BCMA Therapy in Multiple Myeloma: A Single-Center Experience	6
MM-530 Interventions and Outcomes of Multiple Myeloma Patients Progressing after BCMA-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy	6
AML-396 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Initial Results of a Novel, Ongoing BPDCN International Registry Program	6
MM-341 Clinical Characteristics and Risk of Progression in Patients With Monoclonal Gammopathy of Uncertain Significance (MGUS): Long-Term Experience in a Single Tertiary Hospital	6
Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma	6
CLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic Leukemia	6
ALL-004 Philadelphia Chromosome-Positive T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma: A Rare Case Report	6
POSTER: AML-331 Utility of Echocardiogram in Neutropenic Patients With Gram Positive Bacteremia – A Retrospective Study	6
P-019: Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed/refractory multiple myeloma patients treated with idecabtagene vicleucel (ide-ce	6
Poster: CT-132 Outcome of Sex-Mismatched Allogeneic Hemopoietic Stem Cell Transplantation from Human Leukocyte Antigen–Identical Sibling Donors in Patients With Hematologic Diseases	6
POSTER: TCL-196 Hepatosplenic T-Cell Lymphoma in Adolescents and Young Adults: A Case Report	6
POSTER: AML-132 QuANTUM-First Trial: FLT3–Internal Tandem Duplication (FLT3-ITD)–Specific Measurable Residual Disease (MRD) Clearance Is Associated With Improved Overall Survival (OS)	6
MPN-469 Rusfertide (PTG-300) Treatment Interruption Reverses Hematological Gains and Upon Reinitiation, Restoration of Clinical Benefit Observed in Patients With Polycythemia Vera	6
AML-156 Early Deaths in Patients With Newly Diagnosed Acute Promyelocytic Leukemia: A Single-Center Retrospective Study From a General Hospital	6
EXABS-134-ALL Dual CAR T-Cell for ALL	6
POSTER: ALL-020 Localized and Generalized Lymphadenopathy Referred to 3 Tertiary Pediatric Centers Over 6 Years: The Alarming Signs	6
CLL-240 Frequency of IKZF3 L162R Mutation in B-Cell Lymphoproliferative Disorders	6
POSTER: AML-260 A Metabolically Optimized, Non-Cytotoxic Low-Dose Weekly Decitabine/Venetoclax Regimen in MDS and AML	6
AML-053 Assessment of Minimal Residual Disease in Patients With Adult Acute Myeloid Leukemia: Single Egyptian Center Experience	6
Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome	6
Poster: MPN-238 Single-Cell RNA Profiling of Myelofibrosis Patients Reveals Pelabresib-Induced Decrease of Megakaryocytic Progenitors and Normalization of CD4+ T Cells in Peripheral Blood	6
P-247: Addressing the knowledge gap to optimize treatment sequencing for patients with relapsed/refractory multiple myeloma	6
Poster: CT-329 CD19-Directed Chimeric Antigen Receptor T Cell Therapy in Waldenström Macroglobulinemia: Initial Experience in Two Clinical Trials	6
P-206: Antibodies to omicron variants are maintained in newly diagnosed MM patients on lenalidomide, cyclophosphamide, bortezomib and dexamethasone (RCyBorD): results from the UK RADAR/Myeloma XV Tria	6
POSTER: ABCL-222 Diffuse Large Cell Lymphoma of the Uterus Presented With Vaginal Bleeding: A Case Report	6
MDS-556 Comparison of Demographics, Disease Characteristics and Outcomes Between Black and White Patients With Myelodysplastic Syndrome: A Population-Based Study	6
P-262 Retreatment with previously refractory drugs in multiple myeloma	5
P-287 Isatuximab plus pomalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma in real life context in France: IMAGE subgroup analysis based on subgroups of interest	5
Recent Advances in the Use of Chimeric Antigen Receptor–Expressing T-Cell Therapies for Treatment of Multiple Myeloma	5
P-373 Functional genomics of genes residing in the minimally deleted chromosome 17p13 region in multiple myeloma: therapeutic implications	5
MPN-105 An Unusual Presentation of Erdheim-Chester Disease: A Case Report	5
IBCL-094 A Primary Pulmonary Determination—A Rare Form of Marginal B-Cell Lymphoma: A Case Report	5
Corrigendum to P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refra	5
SOHO State of the Art Updates and Next Questions \| Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia—How to Define the Treatment Value?	5
P-240 Efficacy and safety of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and prior noncellular anti-BCMA therapy: CARTITUDE-2 cohort C	5
P-067 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma	5
A Multistakeholder Qualitative Analysis of Barriers to Autologous Stem Cell Transplantation for Multiple Myeloma	5
MM-034 PDL-1 expression in Multiple Myeloma Patients Associated with Systemic Lupus Erythematosus	5
Predictors and Outcomes of Clostridioides difficile Infection in Hematopoietic Stem Cell Transplant: A National Readmission Database Analysis, 2018-2020	5
P-198 Impact of blocking the CD47 axis on phagocytosis of myeloma cells treated with CD38 antibodies and proteasome inhibitors	5
P-267 Teclistamab is safe and effective in relapse refractory multiple myeloma patients with end stage renal disease: a case series	5
P-333 Multi-omic analysis of multiple myeloma subtypes reveals epigenetic programs of high-risk disease	5
Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospec	5
Safety, Feasibility, and Efficacy of Exercise Interventions for People With Multiple Myeloma: A Systematic Review	5
Otolaryngologist's Approach to Acute Purulent Tonsillitis as an Early Symptom of Lymphoma	5
Table of Contents	5
P-372 Transcriptomic expression of BMP-2, BMP-6 and Smad6 genes in newly diagnosed and relapsed multiple myeloma patients	5